MarketPulse

Phase 2 trials

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Keros Therapeutics' Rinvatercept Shows Promise in Neuromuscular Disease Trial

Keros Therapeutics presented Phase 1 data for rinvatercept showing good tolerability and increased muscle mass, planning Phase 2 trials in DMD and ALS.
KROSPhase 1 clinical trialPhase 2 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Upstream Bio to Present Pipeline Progress at Major Healthcare Conferences

Upstream Bio will present pipeline progress at two March 2026 healthcare conferences, discussing its TSLP receptor antagonist in Phase 2 trials for severe respiratory conditions.
UPBinvestor conferenceverekitug
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Expands Spyre Therapeutics Position as Stock Climbs 63% YoY

Commodore Capital increases Spyre Therapeutics stake to $78.24M as stock surges 63% YoY. Biotech firm has $757M cash and expects Phase 2 data in 2026.
ALKSSYRERLAYXENEbiotechbalance sheet strength